Michael Lowry (Tipperary, Independent)
Link to this: Individually | In context | Oireachtas source

474. To ask the Minister for Health the reasons pembrolizumab is reserved for the first-line treatment of certain cancers; the reason it is not approved for those currently receiving second-line cancer treatment therapy; if he will review the case of a person (details supplied); to initiate discussions with HSE officials to review the criteria for pembrolizumab as a second-line treatment option, emphasising the urgency and potential benefits of pembrolizumab for breast cancer treatment; and if he will make a statement on the matter. [27130/24]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.